File downloaded on 2026-11-21
Source URL: https://medicines.health.europa.eu/veterinary/en/600000049912

Dexa-ject 2 mg/ml solution for injection for cattle, horses, pigs, dogs and cats

Authorised

- Dexamethasone sodium phosphate

Product identification

Medicine name:
Dexa-ject 2 mg/ml solution for injection for cattle, horses, pigs, dogs and cats

Active substance:
Dexamethasone sodium phosphate

Target species:
Horse
Cattle
Dog
Cat
Pig

Route of administration:
Intraarticular use
Intramuscular use
Intravenous use

Product details

Active substance and strength:
Dexamethasone sodium phosphate
2.63 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:
Intraarticular use:

- **Horse**
  - Meat and offal. 8 day
  - Milk. no withdrawal period

Not authorised for use in horses producing milk for human consumption.

Intramuscular use:

- **Cattle**
  - Meat and offal. 8 day
  - Milk. 72 hour

- **Horse**
  - Meat and offal. 8 day
  - Milk. no withdrawal period

Not authorised for use in horses producing milk for human consumption.

- **Pig**
  - Meat and offal. 2 day

Intravenous use:

- **Horse**
  - Meat and offal. 8 day
  - Milk. no withdrawal period

Not authorised for use in horses producing milk for human consumption.

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QH02AB02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Norway

Available in:
Norway

Package description:
Cardboard box with 1 colourless, type I glass vial of 100 ml which is closedwith a bromobutyl rubber stopper and sealed with an aluminium cap.
Cardboard box with 1 colourless, type I glass vial of 50 ml which is closedwith a bromobutyl rubber stopper and sealed with an aluminium cap.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Dopharma Research B.V.

Marketing authorisation date:
31/05/2018

Manufacturing sites for batch release:
Dopharma B.V.

Responsible authority:
Norwegian Medical Products Agency

Authorisation number:
17-11960

Date of authorisation status change:
20/02/2019

Reference member state:
Ireland

Procedure number:
IE/V/0293/001

Concerned member states:
Austria Belgium Bulgaria Croatia Czechia Denmark Estonia Finland France Germany Greece Hungary Iceland Italy Latvia Lithuania Netherlands Norway Poland Romania Slovakia Spain Sweden

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 3/05/2024
Updated on: 14/03/2026
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.